



**Murdoch**  
UNIVERSITY

## MURDOCH RESEARCH REPOSITORY

*This is the author's final version of the work, as accepted for publication following peer review but without the publisher's layout or pagination.  
The definitive version is available at*

<http://dx.doi.org/10.1111/jir.12026>

Glasson, E.J., Dye, D.E. and Bittles, A.H. (2013) The triple challenges associated with age-related comorbidities in Down syndrome. *Journal of Intellectual Disability Research*, 58 (4). pp. 393-398.

<http://researchrepository.murdoch.edu.au/14299/>

Copyright: © 2013 The Authors  
It is posted here for your personal use. No further distribution is permitted.

**The triple challenges associated with age-related comorbidities  
in Down syndrome**

Glasson EJ<sup>1</sup>, Dye DE<sup>2</sup> and Bittles AH<sup>3,4</sup>

<sup>1</sup>School of Population Health, University of Western Australia, Perth, Australia

<sup>2</sup>School of Biomedical Science, Curtin University of Technology, Perth, Australia

<sup>3</sup>Centre for Comparative Genomics, Murdoch University, Perth, Australia

<sup>4</sup>School of Medical Sciences, Edith Cowan University, Perth, Australia

Corresponding Author: Dr Emma J Glasson ([emma.glasson@uwa.edu.au](mailto:emma.glasson@uwa.edu.au))

The authors declare no conflict of interest.

### Survival trends in Down syndrome

Down syndrome has a population prevalence of 1/650 to 1/1,000 live births<sup>[1,2]</sup>. Despite a high uptake of prenatal testing and elective termination of affected pregnancies the birth prevalence of Down syndrome has remained stable or even increased during the last two decades in a number of countries<sup>[1,3]</sup>. The principal reason for this phenomenon is the positive association between Down syndrome conceptions and advanced maternal age<sup>[4]</sup>, coupled with the continuing trend of women delaying child-bearing to later ages<sup>[3]</sup>.

In developed countries over 90% of children born with Down syndrome now live to 10 years of age and median life expectancy at birth has increased to approximately 60 years, up from just 12 years of age in the 1950s<sup>[5,6]</sup>. Survival estimates have improved significantly through by early correction of congenital heart defects<sup>[7-9]</sup> as well as more focused treatment of infections, better enhanced nutrition, and improved general health care.

### Comorbidities in Down syndrome

Down syndrome is associated with a wide range of comorbidities across different life phases<sup>[1]</sup>. Early childhood disorders have been well described, for example, congenital heart defects<sup>[10]</sup>, reduced immunological function<sup>[11]</sup>, and a predisposition to acute lymphocytic leukaemia<sup>[12]</sup> which can continue to pose serious concerns throughout the lifespan. However, other major comorbidities develop during and after childhood with some disease states only diagnosed at advanced ages<sup>[13]</sup>. In addition, Down syndrome is associated with premature ageing, becoming apparent around 40 years of age, i.e. some 20 years earlier than in members of the general population. Therefore with a median life expectancy of approximately 60 years individuals may be at risk of a range of age-related diseases over an extended period of their lives<sup>[1,14]</sup>.

To examine these issues data were collated from studies which observed five common comorbidities affecting adults with Down syndrome, visual and hearing defects, epilepsy, thyroid disorders, and Alzheimer disease, at specific age intervals<sup>[15-22]</sup>. Only studies with data reported per decade of life were included. Figure 1 depicts how the prevalence of most of these conditions increases sharply after 40 years of age, and how at this age people with Down syndrome are subject to a high risk of significant multiple morbidities and a consequent need for ongoing specialist care. Secondary conditions such as osteoporosis, obesity, diabetes and poor dentition are also expected to develop with advancing age<sup>[13]</sup>, with their ill-effects exacerbated by long-term medication, polypharmacy, immobility, and general inactivity.

Formatted: Superscript

### Challenges in the delivery of health care to people with Down syndrome

Three main questions relating inged to the delivery of health care can be identified:

## 1. Are comorbidities being detected in a timely manner~~adequately~~?

Relatively few published studies have included sufficient numbers of adult cases to demonstrate the specific age-related disease patterns that emerge in Down syndrome. Besides small sample sizes, inappropriate descriptors such as ‘above 18 years’ or ‘under 50 years vs over 50 years’ are often applied. Analyses of this nature are insufficiently ~~robust or~~ precise to identify the important decadal changes in health that commonly arise in people with Down syndrome. The paucity of available data implies that health professionals may be inadequately informed about the timing and nature of Down syndrome comorbidities, thus precluding the adoption of appropriate screening schedules.

Sets of health guidelines for adults with Down syndrome have nevertheless been published to encourage primary health care providers to perform regular health checks<sup>[23]</sup>. However t~~he~~ guidelines are, ~~however~~, generally broad in nature, they occasionally vary in the advice proffered, and they usually are compiled without consideration of the timing of symptom onset or possible interactions between comorbid conditions. It is generally recommended that annual medical appointments are arranged to review medications, screen for expected comorbidities, and consider the emergence of prospective illnesses<sup>[24]</sup>. But European studies have shown that many adults with Down syndrome fail to receive regular medical appointments and therefore health checks are not applied<sup>[25,26]</sup>. Of greater concern, an Australian survey of children and adolescents with Down syndrome indicated a decreasing mean number of regular general practitioner visits even by late childhood<sup>[27]</sup>.

In the absence of formally implemented strategies for adult health care it is likely that: i) many people with Down syndrome are not regularly screened; ii) interventions are only introduced when problems have become clinically apparent, with the onset of treatments delayed; iii) different conditions are treated in isolation; and iv) untreated health problems may result in additional disadvantageous complications. Communication difficulties frequently prevent individuals with the disorder from conveying symptoms ~~adequately~~ and providing descriptive information, with awareness of illness initially noticed via behavioural changes that require interpretation by a vigilant carer or clinician. It therefore is important for carers and physicians to be aware of appropriate regimens to maintain health with regular screening for emerging health issues<sup>[28]</sup>, particularly as people with intellectual disability are seldom targeted in community health promotion programmes<sup>[29]</sup>.

## 2. Is the clinical progression of Down syndrome adequately understood?

The combination of age-related comorbidities and positive improvements in survival statistics over the last half-century necessitates a more detailed investigation into the natural progression and

~~longitudinal patterns of comorbidities of the life course in of~~ Down syndrome, ~~especially since~~. As the phenomenon of old age in ~~people with the disorder Down syndrome~~ is relatively recent, ~~detailed investigation into the natural progression of the disorder and longitudinal patterns of comorbidities is needed~~. Although certain comorbidities have been identified ~~that and~~ are common to ~~mostany~~ people with Down syndrome, ~~many cases not all people~~ exhibit ~~dissimilar health the same health~~ histories<sup>29</sup> suggesting particular health trajectories within Down syndrome itself. Isolating and ascribing these patterns ~~of disease~~ to particular subgroups will increase our understanding of their predetermined health outcomes and the requirement for more personalised care schedules.

~~An individual's The~~ birth cohort should be considered as an important variable in longitudinal analyses, ~~as since people individuals~~ born in more recent decades predictably would have experienced different care protocols which in turn would impact on their overall health status. A prime example of this transition in care is the highly significant ~~positive~~ impact of early surgical intervention on the survival of the estimated 40-50% of infants with Down syndrome diagnosed with a congenital heart defect<sup>[30,318,30]</sup>.

Formatted: Superscript

### 3. Who is responsible for the provision of care?

According to normalisation principles people with Down syndrome are encouraged to live in mainstream society<sup>[31]</sup> with their wellbeing largely dependent on caregivers at home or in community placements. An inadvertent adverse effect of normalisation has been a reduction in the number of appropriately trained and experienced health professionals<sup>[32,33]</sup>, resulting in increased workloads for general practitioners and greater burdens on families and carers. The development of additional illnesses in the fourth to sixth decades ensures that a lengthy period of specialist care will be required during the remaining years of life, now potentially spanning more than 30 years. However, the management of health care for people after 18 years of age is ill-defined, with continuity of care often fragmented, reluctance from both families and paediatric practitioners to initiate the transition to adult-based services<sup>[34]</sup>, and in some cases a preference to remain linked to paediatric services<sup>[35]</sup>.

Formatted: Not Superscript/ Subscript

In a US cohort study of people with Down syndrome (median age ~~of~~ 28 years), half of the individuals ~~investigated~~ continued to utilize child-focused providers in some capacity<sup>[20]</sup>. This blurring of the transition to adulthood creates the incongruity that adults with Down syndrome are encouraged to be independent members of society, yet their health care regimens remain largely unmapped. ~~Controversy also Questions~~ remains ~~with respect to the surrounding which~~ medical specialities ~~that~~ can most appropriately deliver ~~their~~ health care ~~for people with Down syndrome~~ in adulthood and old age, and whether community-based practitioners are sufficiently knowledgeable or experienced to administer the levels of advice and support needed.


## Conclusion

The triple challenges identified exist because of the significant increase in the life expectancy of people with Down syndrome in recent decades, equating to almost one additional year of survival for every year passed<sup>[5]</sup>. [Detailed research into ~~related changes in~~ their age-related health profiles is therefore essential](#), both for people with the disorder and their families, [is essential if progress towards health and social equality for people with Down syndrome is to continue](#).

Word count n = 1,[299504](#)

**Figure 1 legend:**

—Probability of developing five common disease states per decade of life for people with Down syndrome compared to the general population: a) Visual impairment <sup>[16,22]</sup>; b) Hearing impairment <sup>[15,22]</sup>; c) Epilepsy <sup>[18,22]</sup>; d) Thyroid disorders <sup>[19,22]</sup>; e) Dementia <sup>[17,21]</sup>.



## References

1. Bittles AH, Bower C, Hussain R & Glasson EJ (2007). The four ages of Down syndrome. *European Journal of Public Health*, 17(2):221-225.
2. Stoll C, Alembik Y, Dott B & Roth MP (1998). Study of Down syndrome in 238,942 consecutive births. *Annales de Génétique*, 41(1):44-51.
3. Morris JK & Alberman E (2009). Trends in Down's syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down Syndrome Cytogenetic Register. *British Medical Journal*, Oct 26;339:b3794.
4. Morris JK (2008). Down's syndrome live births in England and Wales: the effect of the National Fetal Anomaly Screening Programme. *Genus*, 64(91-97).
5. Bittles AH & Glasson EJ (2004). Clinical, social and ethical implications of changing life expectancy in Down syndrome. *Developmental Medicine and Child Neurology*, 46(4):282-286.
6. Glasson EJ, Sullivan SG, Hussain R, Petterson BA, Montgomery PD & Bittles AH (2002). The changing survival profile of people with Down's syndrome: implications for genetic counselling. *Clinical Genetics*, 62:390-393.
7. Eskedal L, Hagemo P, Eskild A, Aamodt G, Selier KS & Thailow E (2004). A population-based study of extra-cardiac anomalies in children with congenital malformations. *Cardiology in the Young*, 14(6):600-607.
8. Hijii T, Fukushige J, Igarashi H, Takahashi N & Ueda K (1997). Life expectancy and social adaptation in individuals with Down syndrome with and without surgery for congenital heart disease. *Clinical Pediatrics (Phila)*, 36(6):327-332.
9. Masuda M, Kado H, Tanoue Y, Fukae K, Onzuka T, Shiokawa Y, Shiorota T & Yasui H (2005). Does Down syndrome affect the long-term results of complete atrioventricular septal defect when the defect is repaired during the first year of life? *European Journal of Cardiothoracic Surgery*, 27(3):405-409.
10. Freeman SB, Taft LF, Dooley KJ, Allran K, Sherman SL, Hassold TJ, Khoury MJ & Saker DM (1998). Population-based study of congenital heart defects in Down syndrome. *American Journal of Medical Genetics*, 80(3):213-217.
11. Kusters MA, Versteegen RH, Gemen EF & de Vries E (2009). Intrinsic defect of the immune system in children with Down syndrome: a review. *Clinical and Experimental Immunology*, 156(2):189-193.
12. Hasle H, Clemmensen IH & Mikkelsen M (2000). Risks of leukaemia and solid tumours in individuals with Down's syndrome. *Lancet*, 355(9199):165-169.
13. Urbano RC, ed. *International Review of Research in Mental Retardation. Vol. 39, Health Issues in Down Syndrome*. 2010, Academic Press: New York.
14. Bittles AH & Glasson EJ (2010). Increased longevity and the comorbidities associated with intellectual and developmental disability, in *Comorbidities in Developmental Disorders*, M. Bax and C. Gillberg, Editors, Mac Keith Press: London. p. 125-141.
15. Access Economics, *Listen Hear! The economic impact and cost of hearing loss in Australia*. 2006.
16. Australian Institute for Health and Welfare (AIHW), *Vision problems among older Australians. Bulletin no. 27. AIHW cat. No. AUS 60*. 2005, Australian Institute for Health and Welfare: Canberra.

17. Australian Institute of Health and Welfare (AIHW), *Dementia in Australia: National data analysis and development. AIHW cat. no. AGE 53*. 2006, Australian Institute of Health and Welfare: Canberra, Australia.
18. Banerjee PN & Hauser WA, *Incidence and prevalence*, in *Epilepsy: A Comprehensive Textbook, Volume 1*, J.E.a.T. Pedley, Editor. 2008, Lippincott, Williams and Wilkins: Philadelphia. p. 45-56.
19. Gibbons V, Conaglen JV, Lillis S, Naras V & Lawrenson R (2008). Epidemiology of thyroid disease in Hamilton (New Zealand) general practice. *Australia and New Zealand Journal of Public Health*, 32(5):421-423.
20. Jensen KM & Davis MM (2012). Health care in adults with Down syndrome: a longitudinal cohort study. *Journal of Intellectual Disability Research*, doi: 10.1111/j.1365-2788.2012.01589.x.
21. Kapell D, Nightingale B, Rodriguez A, Lee JH, Zigman WB & Schupf N (1998). Prevalence of chronic medical conditions in adults with mental retardation: Comparison with the general population. *Mental Retardation*, 36(4):269-279.
22. van Schrojenstein Lantman-de Valk HMJ, van den Akker M, Maaskant MA, Haveman MJ, Urlings HFJ, Kessels AGH & Crebolder HFJM (1997). Prevalence and incidence of health problems in people with intellectual disability. *Journal of Intellectual Disability Research*, 41(1):42-51.
23. Määttä T, Määttä J, Tervo-Määttä T, Taanila A, Kaski M & Iivanainen M (2011). Healthcare and guidelines: a population-based survey of recorded medical problems and health surveillance for people with Down syndrome. *Journal of Intellectual & Developmental Disability*, 36(2):118-126.
24. Tracy J (2011). Australians with Down syndrome--health matters. *Australian Family Physician*, 40(4):202-208.
25. Bertoli M, Biasini G, Calignano MT, et al. (2011). Needs and challenges of daily life for people with Down syndrome residing in the city of Rome, Italy. *Journal of Intellectual Disability Research*, 55(8):801-820.
26. Henderson A, Lynch SA, Wilkinson S & Hunter M (2007). Adults with Down's syndrome: the prevalence of complications and health care in the community. *British Journal of General Practice*, 57(534):50-55.
27. Geelhoed EA, Bebbington A, Bower C, Deshpande A & H L (2011). Direct health care costs of children and adolescents with Down syndrome. *Journal of Pediatrics*, 159(4):541-545.
28. Martínez-Leal R, Salvador-Carulla L, Linehan C, et al. (2011). The impact of living arrangements and deinstitutionalisation in the health status of persons with intellectual disability in Europe. *Journal of Intellectual Disability Research*, 55(9):858-872.
29. Krahn GL, Hammond L & Turner A (2006). A cascade of disparities: health and health care access for people with intellectual disabilities. *Mental Retardation and Developmental Disabilities Research Reviews*, 12(1):70-82.
30. Freeman SB, Bean LH, Allen EG, Tinker SW, Locke AE, Druschel C, Hobbs CA, Romitti PA, Royle MH, Torfs CP, Dooley KJ & Sherman SL (2008). Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project. *Genetics in Medicine*, 10(3):173-180.
31. Nirje B (1969). The normalization principle and its human management implications, in *Changing Patterns in Residential Services for the Mentally Retarded*, R.B. Kugel and W.

Wolfensberger, Editors, President's Committee on Mental Retardation: Washington DC.  
p. 179-195.

32. Dovey S & Webb OJ (2000). General practitioners' perception of their role in care for people with intellectual disability. *Journal of Intellectual Disability Research*, 44(5):553-561.
33. Nottestad JA & Linaker OM (1999). Psychiatric health needs and services before and after complete deinstitutionalization of people with intellectual disability. *Journal of Intellectual Disability Research*, 43(6):523-530.
34. Scal P (2002). Transition for youth with chronic conditions: primary care physicians' approaches. *Pediatr*, 110(6 Pt 2):1315-1321.
35. Sawyer SM, Blair S & Bowes G (1997). Chronic illness in adolescents: transfer or transition to adult services? *Journal of Paediatrics and Child Health*, 33(2):88-90.

Possible additional ref (see attached abstract):

*Pace, J.E., Shin, M. and Rasmussen, S.A. Understanding physicians' attitudes toward people with Down syndrome. American Journal of Medical Genetics A, 2011. 155A(6): 1258-1263.*

**Formatted:** Font: Italic